{"title":"AR-V7在预测阿比特龙治疗CRPC患者疗效中的价值","authors":"Shuo Wang, Peng Du, Yong Yang","doi":"10.3760/CMA.J.CN112330-20200109-00017","DOIUrl":null,"url":null,"abstract":"Objective \nDetermine the relationship between AR-V7 expression and treatment efficiency of abiraterone. \n \n \nMethods \nA prospective cohort study was conducted to detect CTCs AR-V7 in newly diagnosed CRPC patients, aged ≥18 years who were admitted to the urologic department of Peking University cancer hospital from January 2016 to January 2019, with one or more systemic metastases. All the patients intended to be treated with abiraterone. According to the AR-V7 status, patients were divided into 2 groups (AR-V7 positive and negative). PSA decline time, PSA PFS, clinical status PFS, imaging PFS and CSS are analyzed and compared by t-test and Chi-square between 2 groups. \n \n \nResult \n49 patients were AR-V7 negative and 28 were AR-V7 positive. Compared with AR-V7 positive patients, PSA decline time (72.04±66.92 vs. 190.11±102.44, P=0.000), PSA non-response rate (6.12% vs. 21.4%, P=0.040) are significantly lower in AR-V7 negative patients. PSA PFS(489.17±269.39 vs. 130.56±120, P=0.010), Clinical PFS (551.91±322.05 vs. 261.44±200.85, P=0.018), and Imaging PFS (523.7±223.28 vs. 247.56±202.80, P=0.003) are significantly longer in AR-V7 negative patients. \n \n \nConclusion \nExpression status of AR-V7 is related to the response of abiraterone treatment and the prognosis of the patients. \n \n \nKey words: \nProstatic neoplasms; Castration resistant prostate cancer; Androgen receptor splice variant 7(AR-V7); Abiraterone","PeriodicalId":10343,"journal":{"name":"中华泌尿外科杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The value of AR-V7 in predicting therapeutic efficiency of abiraterone for CRPC patients\",\"authors\":\"Shuo Wang, Peng Du, Yong Yang\",\"doi\":\"10.3760/CMA.J.CN112330-20200109-00017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nDetermine the relationship between AR-V7 expression and treatment efficiency of abiraterone. \\n \\n \\nMethods \\nA prospective cohort study was conducted to detect CTCs AR-V7 in newly diagnosed CRPC patients, aged ≥18 years who were admitted to the urologic department of Peking University cancer hospital from January 2016 to January 2019, with one or more systemic metastases. All the patients intended to be treated with abiraterone. According to the AR-V7 status, patients were divided into 2 groups (AR-V7 positive and negative). PSA decline time, PSA PFS, clinical status PFS, imaging PFS and CSS are analyzed and compared by t-test and Chi-square between 2 groups. \\n \\n \\nResult \\n49 patients were AR-V7 negative and 28 were AR-V7 positive. Compared with AR-V7 positive patients, PSA decline time (72.04±66.92 vs. 190.11±102.44, P=0.000), PSA non-response rate (6.12% vs. 21.4%, P=0.040) are significantly lower in AR-V7 negative patients. PSA PFS(489.17±269.39 vs. 130.56±120, P=0.010), Clinical PFS (551.91±322.05 vs. 261.44±200.85, P=0.018), and Imaging PFS (523.7±223.28 vs. 247.56±202.80, P=0.003) are significantly longer in AR-V7 negative patients. \\n \\n \\nConclusion \\nExpression status of AR-V7 is related to the response of abiraterone treatment and the prognosis of the patients. \\n \\n \\nKey words: \\nProstatic neoplasms; Castration resistant prostate cancer; Androgen receptor splice variant 7(AR-V7); Abiraterone\",\"PeriodicalId\":10343,\"journal\":{\"name\":\"中华泌尿外科杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华泌尿外科杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.CN112330-20200109-00017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华泌尿外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN112330-20200109-00017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
The value of AR-V7 in predicting therapeutic efficiency of abiraterone for CRPC patients
Objective
Determine the relationship between AR-V7 expression and treatment efficiency of abiraterone.
Methods
A prospective cohort study was conducted to detect CTCs AR-V7 in newly diagnosed CRPC patients, aged ≥18 years who were admitted to the urologic department of Peking University cancer hospital from January 2016 to January 2019, with one or more systemic metastases. All the patients intended to be treated with abiraterone. According to the AR-V7 status, patients were divided into 2 groups (AR-V7 positive and negative). PSA decline time, PSA PFS, clinical status PFS, imaging PFS and CSS are analyzed and compared by t-test and Chi-square between 2 groups.
Result
49 patients were AR-V7 negative and 28 were AR-V7 positive. Compared with AR-V7 positive patients, PSA decline time (72.04±66.92 vs. 190.11±102.44, P=0.000), PSA non-response rate (6.12% vs. 21.4%, P=0.040) are significantly lower in AR-V7 negative patients. PSA PFS(489.17±269.39 vs. 130.56±120, P=0.010), Clinical PFS (551.91±322.05 vs. 261.44±200.85, P=0.018), and Imaging PFS (523.7±223.28 vs. 247.56±202.80, P=0.003) are significantly longer in AR-V7 negative patients.
Conclusion
Expression status of AR-V7 is related to the response of abiraterone treatment and the prognosis of the patients.
Key words:
Prostatic neoplasms; Castration resistant prostate cancer; Androgen receptor splice variant 7(AR-V7); Abiraterone
期刊介绍：
Chinese Journal of Urology (monthly) was founded in 1980. It is a publicly issued academic journal supervised by the China Association for Science and Technology and sponsored by the Chinese Medical Association. It mainly publishes original research papers, reviews and comments in this field. This journal mainly reports on the latest scientific research results and clinical diagnosis and treatment experience in the professional field of urology at home and abroad, as well as basic theoretical research results closely related to clinical practice.
The journal has columns such as treatises, abstracts of treatises, experimental studies, case reports, experience exchanges, reviews, reviews, lectures, etc.
Chinese Journal of Urology has been included in well-known databases such as Peking University Journal (Chinese Journal of Humanities and Social Sciences), CSCD Chinese Science Citation Database Source Journal (including extended version), and also included in American Chemical Abstracts (CA). The journal has been rated as a quality journal by the Association for Science and Technology and as an excellent journal by the Chinese Medical Association.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
